Skip to content

Author

Qing-Hua Ke

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward

Highlights • Adjuvant anti-TIGIT plus pembrolizumab shows futility in melanoma.• Combination increases toxicity, including two treatment-related deaths.• Pembrolizumab monotherapy remains standard adjuvant care.• Trial highlights need for active comparators and predictive biomarkers.

Qing-Hua Ke, Shi-Qiong Zhou · 0 citations
Open access Sep 2026

Salvage therapy for radiorecurrent prostate cancer: beyond equipoise – a call for biomarker-driven stratification

Salvage focal therapy and radical prostatectomy show similar cancer-specific survival but differ in complications, and a biomarker-driven, patient-centered approach (including reirradiation) is needed for personalized management.

Qing-Hua Ke, Shi-Qiong Zhou · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.